Another lawsuit has been filed against the makers of the Type 2 diabetes drug, Actos, over allegations that the medication caused the Oregon man to develop bladder cancer.
The lawsuit also alleges that the drug makers were aware of the risks associated with Actos, but failed to reveal those risks to the public. The lawsuit is one of thousands which have been filed nationwide.
The complaint indicates that the man began taking Actos from about April 2009 to May 2012, which is when he began to suffer from bladder cancer, allegedly due to his use of Actos.
The U.S. Food and Drug Administration (FDA) has warned about the risks of taking Actos. In fact, on June 15, 2011, the agency said that taking Actos for more than one year could significantly increase risks for developing bladder cancer. The safety label on Actos was updated to address this risk.
Some research studies provide additional support concerning the link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012 that revealed that Actos users were twice as likely to develop bladder cancer after two years. On July 3, 2012, the Canadian Medical Association Journal reported that patients taking Actos were 22 percent likelier to develop bladder cancer.
Some of the symptoms of bladder cancer are:
- Blood in the urine
- Frequent urination
- Feeling pain when urinating
The makers of Actos have been embroiled in a growing number of lawsuits that allege the Type 2 diabetes drug caused plaintiffs to develop bladder cancer. In the first of some 3,000 Actos injury lawsuits to go to trial, jurors found Takeda Pharmaceutical must pay $6.5 million in damages to a California man who was diagnosed with terminal cancer in 2011 and had taken Actos for more than four years.
Parker Waichman LLP filed this lawsuit, on behalf of the Oregon man, on August 15, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-2471). This case is one of thousands of cases filed as part of the multidistrict litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299).
Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as defendants. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.